<DOC>
	<DOC>NCT00531401</DOC>
	<brief_summary>The purpose of this study is to determine whether Salirasib is effective to shrink or prevent the growth of the tumors associated with non-small cell lung cancer in both patients who are newly diagnosed or have recurrent disease.</brief_summary>
	<brief_title>Study of Salirasib to Treat Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Farnesylthiosalicylic acid</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>Age 18 or older NonSmall Cell Lung Cancer not amenable to curative therapy with surgery or radiation Measurable disease Adenocarinoma of the lung, have not received prior chemotherapy for the malignancy and has a ≥ 15 pack year history of smoking; OR previously treated with recurrent disease and documented KRAS mutation Last dose of radiotherapy &gt; 3 weeks prior to study entry and recovered from all acute toxicities associated with the prior therapy No history of another malignancy in the past 5 years except treated nonmelanomatous skin cancer or superficial bladder cancer or carcinomainsitu of the cervix Karnofsky Performance status of 70 or greater Body Weight &gt; 50 kg Life expectancy ≥ 3 months Serum Creatinine ≤2.0 mg/dL, total bilirubin ≤ 2.0 mg/dL, ALT and AST ≤ 3x ULN, alkaline phosphatase ≤ 5x ULN, WBC &gt; 3000/mm³, ANC ≥ 1500/mm³, platelets ≥ 100,000/mm³, hemoglobin ≥ 10g/dL. No coexisting cardiac or medical problems that would limit compliance in the study Willing to undergo blood sampling for pharmacokinetic analysis Negative pregnancy test, if applicable Evidence of active heart disease including myocardial infarction within previous 3 months Active infectious process Active central nervous system metastases (requiring increasing doses of corticosteroids over the prior month, known progressing lesions) Pregnant or lactating Major surgery without full recovery or major surgery within 3 weeks prior to treatment start QTc Interval &gt; 470 msec Gastrointestinal tract disease resulting in inability to take or absorb oral medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Non-Small-Cell Lung</keyword>
</DOC>